On or around 07/31/2020 (Date of last review)
Filing Date: December 27, 2018
According to the Complaint, Immunomedics purports to be a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer.
The Complaint alleges that during the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts.
On September 10, 2019, the Court issued an Order consolidating cases and appointing co-lead Plaintiffs and co-lead Counsel. Lead Plaintiffs filed a consolidated Complaint on November 18. Defendants filed a Motion to Dismiss the consolidated Complaint on January 17, 2020. On July 31, 2020, the Court denied the Defendants' Motion to Dismiss.
Company & Securities Information
Defendant: Immunomedics, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: IMMU
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.